STOCKS TELEGRAPH

Tag: Corbus Pharmaceuticals

  • Rally Continues For Corbus (CRBP) Stock After-Hours

    Rally Continues For Corbus (CRBP) Stock After-Hours

    A persistent upswing was observed on Tuesday in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP). Corbus stock continued the rally into the after-hours trading session, when the company’s stock increased by 13.28% to $28.50. This came after a notable rise of 35.12% during the regular trading session, which ended at $25.16. One explanation for the increased momentum was the execution of a strategic equity plan.

    In a recent announcement, Corbus (CRBP) stated that it intends to carry out an underwritten RPO, in which it would sell shares of its ordinary stock or, if preferred, pre-funded warrants to specific investors for the acquisition of shares. For all securities included in this offering, Corbus will be the sole vendor.

    The completion of the offering, as well as its size and terms, is contingent upon market conditions, with no guaranteed assurance of its occurrence or specific parameters. The net proceeds from this offering are earmarked for funding the clinical development of its pipeline, alongside utilization for working capital and other corporate purposes.

    Furthermore, during a significant event, data from the first-in-human clinical study of CRB-701 was presented as a poster by CRBP’s development partner, CSPC Pharmaceutical Group, at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).

    CRB-701, equipped with innovative antibody and next-generation linker technology, demonstrates a distinctive pharmacokinetic profile compared to enfortumab vedotin (EV), showcasing a current safety profile without peripheral neuropathy and skin rash—known dose-limiting toxicities for EV.

    This distinction holds promise for metastatic urothelial carcinoma (mUC) patients and other solid tumors expressing nectin-4, such as cervical cancer. Upon evaluation of CRB-701’s emerging profile with an eminent expert in genitourinary cancers, the positive clinical responses observed in nectin-4 positive mUC and cervical cancer patients are encouraging.

    Additionally, the early clinical safety data presents the initial evidence of CRB-701’s clinical activity across various nectin-4 expressing tumors, warranting further investigation into the compound’s safety and efficacy. As the ongoing clinical study advances in China with partner CSPC, Corbus is strategically planning to initiate a clinical study in the United States in Q1 2024 under an already open Investigational New Drug (IND) application.

  • Biotech Roundup &The delivery of the Pfizer’s vaccine to U.S. – starts Today

    Biotech Roundup &The delivery of the Pfizer’s vaccine to U.S. – starts Today

    This weekend, the U.S. government is packaging millions of doses of the coronavirus vaccine from Pfizer and BioNTech for distribution to places around the country, a mammoth logistics task in favor of what could be the most difficult immunization campaign in history.

    In delivering the vaccine, which is delicate and needs careful care, FedEx and UPS would play key roles. At the terminal, shipments can gain preferential entry. If a plane arrives to land with vaccinations, other passenger flights may have to loop around to wait for their chance.

    The arrival of the first vaccines comes as the virus continues to rage through the USA, with more than 207,000 new cases identified on Saturday by authorities. That took the number to more than 16 million, the most in the world by far. For the first time on Wednesday, more than 3,000 deaths were reported, and the country’s number is nearing 300,000.

    vTv Therapeutics Inc. (NASDAQ:VTVT) shares were trading up 41.55% at $3.10 at the time of writing on Friday. The firm on November 25, 2020 announced common stock purchase agreement for up to $47 million with Lincoln Park Capital.

    vTv Therapeutics Inc. (NASDAQ:VTVT) share price went from a low point around $1.44 to briefly over $4.23 in past 52 weeks, though shares have since pulled back to $3.10. VTVT market cap has remained high, hitting $161.79M at the time of writing, giving it price-to-sales ratio of more than 7350.

    If we look at the recent analyst rating VTVT, H.C. Wainwright initiated coverage on VTVT shares with a Buy rating.

    aTyr Pharma Inc. (LIFE) last closed at $4.64, in a 52-week range of $2.13 to $7.62. The company on November 13, 2020 released third quarter results and provided a corporate update.

    ADiTx Therapeutics Inc. (ADTX) stock soar by 3.77% to $2.48. The firm reported on December 8, 2020, that it will present at the 13th annual LD Micro main event conference on Tuesday, December 15, 2020 at 11:00 AM EST / 8:00 AM PST.

    9 Meters Biopharma Inc. (NASDAQ:NMTR) Shares headed falling, lower as much as -11.75%.

    Iterum Therapeutics plc (NASDAQ:ITRM) rose 11.72% after gaining more than $0.1 on Friday. The biotechnology firm declared on December 7,2020, filing of US patent application based on favorable written opinion of the International Search Authority.

    Vaxart Inc. (VXRT) last closed at $7.44, in a 52-week range of $0.28 to $17.49.

    Catabasis Pharmaceuticals Inc. (CATB) stock soar by 14.51% to $2.21. The most recent rating by Wedbush, on November 02, 2020, is at a Neutral.

    Advaxis Inc. (NASDAQ:ADXS) Shares headed rising, higher as much as 3.56%. The company on November 27, 2020 reported the closing of $9.2 million public offering. The most recent rating by Barclays, on August 03, 2016, is at an Overweight.

    Xeris Pharmaceuticals Inc. (NASDAQ:XERS) rose 11.74% after gaining more than $0.48 on Friday following an announcement from the company that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive Opinion for Ogluo™ (glucagon).

    Novavax Inc. (NVAX) last closed at $124.88, in a 52-week range of $3.65 to $189.40. The firm on December 9, 2020, declared the appointment of Margaret G. McGlynn, R. Ph. to its board as an independent director. Analysts have a consensus price target of $186.20.

    Corbus Pharmaceuticals Holdings Inc. (CRBP) stock soar by 1.52% to $1.34. The most recent rating by ROTH Capital, on September 08, 2020, is at a Neutral.

    Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares headed falling, lower as much as -1.23%. The most recent rating by Mizuho, on April 22, 2020, is at a Neutral.

    Novan Inc. (NASDAQ:NOVN) rose 1.10% after gaining more than $0.01 on Friday.

    Nabriva Therapeutics plc (NBRV) last closed at $2.44, in a 52-week range of $3.26 to $18.29. The company recently announced pricing of $15 million public offering.

    Salarius Pharmaceuticals Inc. (SLRX) stock drop by -31.34% to $0.92 after declaring that it has entered into agreements with several institutional and accredited investors to exercise of warrants for $3.5 million of gross proceeds to be used for ongoing development of Seclidemstat. The most recent rating by Ladenburg Thalmann, on April 27, 2020, is at a Buy.